ArticleNPJ science of food2026
Distinct Limosilactobacillus reuteri microcapsule models: construction and therapeutic evaluation in DSS-induced colitis mice.
Article in NPJ science of food, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The limited stability of L. reuteri in liquid formulations during storage, transport, and gastrointestinal transit presents a major challenge for its application as a probiotic. To address this, our study developed two distinct microcapsulation models for L. reuteri A-1, tailored for specific release profiles: slow-release and quick-release model. Utilizing single-factor experiments and response surface methodology, we optimized the encapsulation process, achieving a maximum embedding efficiency of 88.64% for the slow-release model. The quick-release model demonstrated a high cumulative release rate of 83.3%. Structural characterization revealed microcapsules with dense, smooth surfaces and internal porous structures. Storage stability tests confirmed that low temperature (4 °C) best preserved viability. In the DSS-induced murine colitis model, the quick-release model significantly alleviated disease symptoms, including weight loss, colon shortening, inflammatory cytokine imbalance, and mucosal damage. 16S rRNA analysis further showed that the quick-release system helped restore the gut microbiota of colitis mice to a state closer to that of healthy controls. This work establishes a novel technological platform for the controlled release and targeted delivery of probiotics, holding significant promise for the development of live biotherapeutic products.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.